









Appendix: Neurology Data Collection Form

CASE RECORD FORM

1. PATIENT INFORMATION - Please complete the below data as of the date and time of the patient's admission to the ICU			
1.1 PATIENT ECMOCARD/ISARIC NUMBER (from main study CRF):			
1.2 PREVIOUS DIAGNOSIS OF CHRONIC NEUROLOGICAL DISORDER (This option will only be available if 'yes' to chronic neurological condition on SPRINT-SARI form) – select all that apply:			
 Chronic neurodegenerative condition Previous diagnosis of psychological disorder (including mood disorders) Previous delirium History of cerebrovascular disease Other (specify): 			
1.3 PREMORBID MODIFIED RANKIN SCALE (mRS) – based on patient history/interview with family, using mRS scoring system (https://www.mdcalc.com/modified-rankin-scale-neurologic-disability):			
mRS: (between 0 and +6)			
2. CENTRAL NERVOUS SYSTEM (CNS) COMPLICATIONS – Please indicate whether the patient was diagnosed with any new CNS complications during their hospital stay and complete the relevant details			
2.1 DIAGNOSIS OF ISCHEMIC STROKE – neurological deficit due to cerebrovascular occlusion and consequent cerebral infarction. Diagnosis must be confirmed with CT or MRI.			
□ Yes □ No			
2.1a DATE OF DIAGNOSIS (only if 'yes' to 2.1) – specify the date when ischemic stroke was first diagnosed:			
Date of diagnosis:// (DD/MM/YYYY)			
2.2 DIAGNOSIS OF INTRACRANIAL HAEMORRHAGE – bleeding within the skull including intracerebral, subarachnoid, and subdural haemorrhage. Diagnosis must be confirmed with CT or MRI.			
□ Yes □ No			
2.2a DATE OF DIAGNOSIS (only if 'yes' to 2.2) – specify the date when intracranial haemorrhage was first diagnosed:			
Date of diagnosis:/ (DD/MM/YYYY)			





























2.8 DIAGNOSIS OF OTHER CNS COMPLICATION

Please specify:		
2.8a DATE OF DIAGNOSIS (only if 'yes' to 2.8) – specify the date when the neurological complication was first diagnosed:		
Date of diagnosis:/ (DD/MM/YYYY)		
3. PERIPHERAL NERVOUS SYSTEM (PNS) COMPLICATIONS – Please indicate whether the patient was diagnosed with any PNS complications during their hospital stay and complete the relevant details		
3.1 DIAGNOSIS OF GUILLAN-BARRE SYNDROME (GBS) – diagnostic based on the GBS classification group criteria (https://www.nature.com/articles/nrneurol.2013.138):		
□ Yes □ No		
3.1a DATE OF DIAGNOSIS (only if 'yes' to 3.1) – specify the date when GBS was first diagnosed:		
Date of diagnosis:/ (DD/MM/YYYY)		
3.2 DIAGNOSIS OF CRITICAL ILLNESS MYOPATHY/NEUROPATHY – diagnosis based on published criteria (https://www.ncbi.nlm.nih.gov/pubmed/21939902):		
☐ Yes☐ No		
3.2a DATE OF DIAGNOSIS (only if 'yes' to 3.2) – specify the date when critical illness myopathy or neuropathy was first diagnosed:		
Date of diagnosis:/ (DD/MM/YYYY)		
3.3a HYPOGEUSIA OR HYPOSMIA:		
□ Yes □ No		
3.3a DATE OF DIAGNOSIS (only if 'yes' to 3.1) – specify the date when hyposmia or hypogeusia was first diagnosed:		
Date of diagnosis:/ (DD/MM/YYYY)		
3.4 DIAGNOSIS OF OTHER NEUROPATHY OR MYOPATHY:		
Please specify:		
3.4a DATE OF DIAGNOSIS (only if 'yes' to 3.4) – specify the date when the neurological complication was first diagnosed:		
Date of diagnosis:/ (DD/MM/YYYY)		















4. FURTHER DETAILS AND OUTCOMES OF NEUROLOGICAL COMPLICATIONS – Please complete the below information regarding specific complications and their respective management and outcomes.

	4.1 TOAST STROKE CLASSIFICATION (if 'yes' to 2.1) - https://radiopaedia.org/articles/toast-classification-in-acute-ischemic-stroke:		
	Large-artery atherosclerosis		
	Cardioembolism		
	Small-vessel occlusion (lacune)		
	Stroke of other determined etiology		
	Stroke of undetermined etiology		
	ational Institutes of Health Stroke Score (if 'yes' to 2.1) – (https://www.mdcalc.com/nih-scale-score-nihss):		
NIHSS	Score: (between 0 and 42)		
4.1b II	MAGING CONFIRMATION OF DIAGNOSIS OF ISCHEMIC STROKE (if 'yes' to 2.1) - select all able:		
	СТ		
	MRI		
	N/A		
	Other (specify):		
4.1c N	IANAGEMENT OF ISCHAEMIC STROKE (if 'yes' to 2.1):		
	Fibrinolysis (alteplase, tenecteplase, etc.)		
	Endovascular thrombectomy		
	Antiplatelet agent		
	Anticoagulation		
	Hemicraniectomy		
4.2 IN	TRACRANIAL HAEMORRHAGE CLASSIFICATION (if 'yes' to 2.2):		
	Intracerebral haemorrhage (focal haemorrhage from a blood vessel within the brain parenchyma)		
	Subarachnoid haemorrhage (bleeding below the arachnoid mater)		
	Subdural haematoma (collection of blood under the dura mater)		
	Other (specify):		
4.2a IN	MAGING CONFIRMATION OF INTRACRANIAL HAEMORRHAGE (if 'yes' to 2.2) - select all		
applica	able:		
	СТ		
	MRI		
	N/A		
	Other (specify):		

4.2b TREATMENT OF INTRACRANIAL HAEMORRHAGE (if 'yes' to 2.2):















	External ventricular drain
	Surgical intervention
	Endovascular intervention
	Supportive therapy/medical management
4.2c Int	racerebral haemorrhage
ICH Scc	re:
4.3 AN	CILLARY TESTING FOR HYPOXIC ISCHAEMIC BRAIN INJURY (if 'yes' to 2.3) - select all ble:
	СТ
	MRI
	EEG
	Somatosensory evoked potentials
	Biochemistry
	N/A
	Other (specify):
4.4 INV	ESTIGATIONS FOR MENINGITIS/ENCEPHALITIS (if 'yes' to 2.4) - select all applicable:
	СТ
	MRI
	CSF studies
	EEG
	N/A
	Other (specify):
4.5 INV	ESTIGATIONS FOR TM/SPINAL CORD PATHOLOGY (if 'yes' to 2.5) - select all applicable:
	MRI
	CSF
	N/A
	Other (specify):
4.5a CL	ASSIFICATION OF TM/SPINAL CORD PATHOLOGY (if 'yes' to 2.5)
	Acute partial TM
	Acute complete TM
	Longitudinally extensive TM
	Acute Flaccid Myelitis (AFM)
4.6 NU	MBER OF DAYS WITH SEIZURES (if 'yes' to 2.6)
Numbe	r of days:
	MULTANEOUS DRUG USE FOR SEIZURE MANAGEMENT – select all drugs which were stered simultaneously when seizure management was most intensive (select all that apply):
	Benzodiazepines (diazepam, lorazepam, midazolam etc.)
	Barbiturate (phenobarbital)















	Phenytoin/fosphenytoin
	Valproate
	Levetiracetam
Ш	Other (specify):
4.7 IN	VESTIGATIONS FOR GBS (if 'yes' to 3.1):
	EMG
	CSF studies
	Biochemistry
	Other (specify):
4.7a TI	REATMENT OF GBS (if 'yes' to 3.1):
	IV-IG
	Plasma exchange
	Other (specify):
4.8 IN\	/ESTIGATIONS FOR CIM/CIN (if 'yes' to 3.2):
	EMG
	CSF studies
	Biochemistry
	Other (specify):
4.8a TI	REATMENT OF CIM/CIN (if 'yes' to 3.2):
	IV-IG
	Plasma exchange
	Other (specify):
4.9 WI	HICH COMPONENTS OF TASTE PERCEPTION ARE AFFECTED? (select all that apply) (only if yes
to 3.3)	
	Sweet
	Salty
	Sour
	Savoury/umami
	None
4.9a O	LFACTORY CHANGES (select all that apply) (only if yes to 3.3):
	Smells smell less strong that they did before (the quality of smell has changed)
	Smells smell different than they did before (the quality of smell has changed)
	Smelling things that aren't there (ex. smell burning when nothing is in fire)
	Sense of smell fluctuates (comes and goes)















5. NEUROIMAGING – please provide de-identified radiology reports for any neuroimaging completed performed during the patient's hospital stay.

5.1 COMPUTED TOMOGRAPHY (CT) HEAD RADIOLOGY REPORT(S) AVAILABLE:	
☐ Yes☐ No	
5.1a DATE OF CT HEAD (only if 'yes' to 5.1) – specify the date when a CT scan of the head performed:	was
Date of diagnosis:// (DD/MM/YYYY)	
5.2b CT HEAD RADIOLOGY REPORT(S):	
Upload:	
5.2 MAGNETIC RESONANCE IMAGING (MRI) BRAIN RADIOLOGY REPORT(S) AVAILABLE:	
☐ Yes☐ No	
5.2a DATE OF MRI BRAIN (only if 'yes' to 5.1) – specify the date when an MRI scan of the performed:	brain was
Date of diagnosis:// (DD/MM/YYYY)	
5.2b MRI BRAIN REPORT(S):	
Upload:	
5.3 MRI SPINE RADIOLOGY REPORT(S) AVAILABLE:	
☐ Yes☐ No	
5.3a DATE OF MRI SPINE (only if 'yes' to 5.1) – specify date when an MRI scan of the spin performed:	e was
Date of diagnosis:// (DD/MM/YYYY)	
5.3b MRI SPINE REPORT(S):	
Upload:	
5.4 If ischemic stroke or intracranial haemorrhage, laterality of lesion.	
□ Right side of brain□ Left side of brain□ Both	

6. SERUM BIOCHEMISTRY – please indicate if any serum biomarkers were measured and record the date of testing and respective results.

6.1 SERUM BIOMARKERS OF NEURONAL INJURY ASSESSED:















	S100B
	NSE
	None of the above
6.1b M	AXIMUM S100 CALCIUM BINDING PROTEIN (S100B) CONCENTRATION AND DATE OF TEST:
Date of	test:// Concentration in ng/mL:
6.1c M	AXIMUM NEURON SPECIFIC ENOLASE (NSE) CONCENTRATION AND DATE OF TEST:
Date of	test:// Concentration in ng/mL:
7. PA	TIENT OUTCOME – to be completed at discharge and 28 days.
7.1 WI	THDRAWAL OF LIFE-SAVING THERAPY:
	Yes
	No
7.1a RI	ASON FOR WITHDRAWAL OF LIFE-SAVING THERAPY (if 'yes' to 7.1)
	Neurologic
	Cardiac
	Respiratory
	Multi-organ
	Futility
	Resource allocation
	Other (specify):
	DIFIED RANKIN SCALE (mRS) AT ICU DISCHARGE - https://www.mdcalc.com/modified-scale-neurologic-disability
mRS: _	(between 0 and +6)
	DIFIED RANKIN SCALE (mRS) AT 28 DAYS POST-DISCHARGE - /www.mdcalc.com/modified-rankin-scale-neurologic-disability
mRS: _	(between 0 and +6)



